Germany My long-term hope is that dialysis will become much less common because we are able to diagnose and treat kidney disease earlier and more effectively Prof. Dr. Jörg Latus is passionate about the future of kidney care and the growing potential to prevent or slow disease progression. As Medical Director…
Germany Collaboration across institutions is not optional – it is necessary. The pace and complexity of the challenges demand it. As CEO of TUM University Hospital Munich, Dr med Martin Siess is trying to close a gap that has long dogged German medicine: strong basic research that rarely makes it to…
Germany Prof Dr med Hanns-Peter Knaebel has moved between the operating table, industry, and hospital leadership in his career a path that now shapes his approach to one of the more ambitious experiments in German healthcare: merging two university hospitals into a single network. As CEO of the newly formed Heidelberg-Mannheim…
Germany Prof Dr Markus M. Lerch, Physician-in-Chief and CEO of Munich University Hospital, oversees more than 2,000 concurrent clinical trials and a EUR 2.2 billion campus rebuild now underway in Bavaria. Dr Lerch explains why Germany’s 1,800-hospital system needs consolidation, how the new Munich Medicine Alliance will streamline trial access for…
Germany Dr Holm Graessner has spent more than 20 years building the infrastructure that rare disease patients in Europe often lack entirely: diagnostic pathways, European reference networks, and academic drug development for conditions too rare to interest any pharmaceutical company. As Managing Director of the Rare Disease Centre at Tübingen University…
USA Dr Maisha Draves, Associate Executive Director of The Permanente Medical Group (TPMG), speaks to the group’s approach to integrating the use of biosimilars across the care network. By focusing on rigorous research evaluation and peer-to-peer education, TPMG has become a national frontrunner in the uptake of formulary inclusion and the…
Europe The goal is not only to generate scientific breakthroughs, but to ensure that these breakthroughs reach patients faster and more reliably Professor Gerd Geisslinger serves as Chair of Clinical Pharmacology at Goethe University Hospital and as Executive Director of the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), which is…
Korea But Korea is genuinely active, with strong resources – scientifically sound, capable, and very motivated Kyong Hwa Park, Professor of Medical Oncology at Korea University College of Medicine, reflects on Korea’s transformation into a global oncology research hub, highlighting the impact of the K-MASTER precision medicine initiative, advances in cancer…
USA Dr David J. Rawlings is the division head of immunology at Seattle Children’s and director of the Center for Immunity and Immunotherapies at Seattle Children’s Research Institute. An immunologist and rheumatologist working at the forefront of cell engineering, his research focuses on therapies that modulate immune responses across cancer, genetic…
Taiwan Joe Yeh describes founding aetherAI to digitise pathology and embed AI into routine diagnostics, addressing inefficiency, subjectivity, and missed disease detection. He explains Taiwan’s rapid adoption, a research-driven market access strategy, flexible pricing, and global expansion across Germany, Japan, and the US, positioning AI-driven pathology as foundational infrastructure for precision…
Taiwan Bringing together clinical scale, academic depth, and a strong engineering mindset, China Medical University Hospital has positioned itself as more than a care provider. In this interview, Dr Der-Yang Cho, Superintendent and Professor of Neurosurgery, explains how the institution operates as an integrated innovation platform, advancing cell and gene therapies,…
USA Priya Kishnani, Director of the Division of Medical Genetics at Duke University School of Medicine, discusses how multidisciplinary care, global collaboration, and rapidly advancing therapeutic technologies are reshaping the rare disease landscape. Drawing on decades of experience across diagnosis, natural history research, and the development of transformative treatments, she outlines…
See our Cookie Privacy Policy Here
